BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) announced two poster presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct 22–26, 2025 in Boston.
Two abstracts: BBO-11818, an oral non-covalent pan-KRAS(ON)/(OFF) inhibitor showing robust anti-tumor activity in KRAS-mutant preclinical models, will be presented in Poster Session A on Oct 23, 12:30–4:00 PM ET by Carlos Stahlhut, PhD. BBO-10203, a first-in-class oral breaker of the RAS:PI3Kα interaction that inhibited tumor growth without inducing hyperglycemia in KRAS mutant models, will be presented in Poster Session C on Oct 25, 12:30–4:00 PM ET by Kerstin Sinkevicius, PhD. Abstracts are available on the AACR website.
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) ha annunciato due presentazioni poster alla conferenza internazionale AACR-NCI-EORTC 2025 su bersagli molecolari e terapie anticancro, dal 22 al 26 ottobre 2025 a Boston.
Due abstract: BBO-11818, un inibitore orale non covalente pan-KRAS(ON)/(OFF) che mostra un'attività antitumorale robusta in modelli preclinici KRAS-mutanti, sarà presentato nella Poster Session A il 23 ottobre, 12:30–16:00 ET da Carlos Stahlhut, PhD. BBO-10203, un interruttore orale di prima classe dell'interazione RAS:PI3Kα che ha inibito la crescita tumorale senza indurre iperglicemia in modelli KRAS-mutanti, sarà presentato nella Poster Session C il 25 ottobre, 12:30–16:00 ET da Kerstin Sinkevicius, PhD. Gli abstract sono disponibili sul sito AACR.
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) anunció dos presentaciones de póster en la Conferencia Internacional AACR-NCI-EORTC 2025 sobre objetivos moleculares y terapias contra el cáncer, del 22 al 26 de octubre de 2025 en Boston.
Dos resúmenes: BBO-11818, un inhibidor oral no covalente pan-KRAS(ON)/(OFF) que demuestra una robusta actividad antitumoral en modelos preclínicos con KRAS mutante, se presentará en la Sesión de Póster A el 23 de octubre, 12:30–16:00 ET, por Carlos Stahlhut, PhD. BBO-10203, un rompedor oral de primera clase de la interacción RAS:PI3Kα que inhibió el crecimiento tumoral sin inducir hiperglucemia en modelos KRAS mutantes, se presentará en la Sesión de Póster C el 25 de octubre, 12:30–16:00 ET, por Kerstin Sinkevicius, PhD. Los resúmenes están disponibles en el sitio web de AACR.
BridgeBio Oncology Therapeutics (나스닥: BBOT)가 2025 AACR-NCI-EORTC 국제 분자 표적 및 암 치료 컨퍼런스에서 두 편의 포스터 발표를 발표했습니다. 일정은 2025년 10월 22일부터 26일까지 보스턴에서 진행됩니다.
두 편의 초록: BBO-11818은 KRAS 변이 전임상 모델에서 강력한 항종양 활성을 보이는 구강 비공유 비가역적 pan-KRAS(ON)/(OFF) 억제제로, 10월 23일 12:30–16:00 ET에 포스터 세션 A에서 Carlos Stahlhut 박사가 발표합니다. BBO-10203은 RAS:PI3Kα 상호작용의 1세대 구강 차단제로 KRAS 변이 모델에서 종양 성장을 억제하고 고혈당을 유발하지 않는다는 내용으로, 10월 25일 12:30–16:00 ET에 포스터 세션 C에서 Kerstin Sinkevicius 박사가 발표합니다. 초록은 AACR 웹사이트에서 확인할 수 있습니다.
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) a annoncé deux affiches lors de la Conférence internationale AACR-NCI-EORTC 2025 sur les cibles moléculaires et les thérapies anticancer, du 22 au 26 octobre 2025 à Boston.
Deux résumés : BBO-11818, un inhibiteur oral non covalent pan-KRAS(ON)/(OFF) montrant une activité antitumorale robuste dans des modèles précliniques KRAS mutés, sera présenté dans la session Posters A le 23 octobre, 12h30–16h00 ET par Carlos Stahlhut, PhD. BBO-10203, un disruptor oral de première classe de l'interaction RAS:PI3Kα qui a inhibé la croissance tumorale sans provoquer d'hyperglycémie dans des modèles KRAS mutés, sera présenté dans la session Posters C le 25 octobre, 12h30–16h00 ET par Kerstin Sinkevicius, PhD. Les résumés sont disponibles sur le site web de l'AACR.
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) kündigte zwei Poster-Präsentationen auf der 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics an, vom 22. bis 26. Oktober 2025 in Boston.
Zwei Abstracts: BBO-11818, ein oraler nicht-kovalenter pan-KRAS(ON)/(OFF) Inhibitor, der robuste anti-tumor Aktivität in KRAS-mutanten präklinischen Modellen zeigt, wird in Poster Session A am 23. Oktober, 12:30–16:00 ET von Carlos Stahlhut, PhD vorgestellt. BBO-10203, ein First-in-Class oral Breaker der RAS:PI3Kα-Interaktion, der das Tumorwachstum in KRAS-mutanten Modellen gehemmt hat, ohne Hyperglykämie zu induzieren, wird in Poster Session C am 25. Oktober, 12:30–16:00 ET von Kerstin Sinkevicius, PhD vorgestellt. Abstracts sind auf der AACR-Website verfügbar.
BridgeBio Oncology Therapeutics (بورصة ناسداك: BBOT) أعلنت عن عرضين في ملصقات المؤتمر الدولي 2025 AACR-NCI-EORTC حول الاستهداف الجزيئي وعلاجات السرطان، في بوسطن من 22 إلى 26 أكتوبر 2025.
مُلخصان: BBO-11818، مثبط فموي غير تساهمي واسع النطاق لـ KRAS(ON)/(OFF) يظهر نشاطًا مضادًا للأورام قويًا في نماذج قبل السريرية KRAS-mutant، سيُعرض في جلسة الملصقات A في 23 أكتوبر، 12:30–4:00 م بتوقيت شرق الولايات المتحدة بواسطة كارلوس ستالهوط، دكتوراه. BBO-10203، كاسر تفاعل فموي من فئة أولى لـ RAS:PI3Kα الذي قاد إلى تثبيط نمو الورم دون تحفيز فرط سكر الدم في نماذج KRAS-mutant، سيُعرض في جلسة الملصقات C في 25 أكتوبر، 12:30–4:00 م بتوقيت شرق الولايات المتحدة بواسطة كيرستين سنيفيسيوس، دكتوراه. الملخصات متاحة على موقع AACR.
BridgeBio Oncology Therapeutics (纳斯达克: BBOT)宣布将在2025年 AACR-NCI-EORTC 国际会议上进行两场海报展示，会议时间为 2025 年 10 月 22–26 日，地点在波士顿。
两份摘要：BBO-11818，一种口服非共价全KRAS(ON)/(OFF)抑制剂，在 KRAS 突变的前临床模型中显示出强劲的抗肿瘤活性，将于 10 月 23 日 12:30–16:00 ET 在海报会场 A 由 Carlos Stahlhut 博士进行报告。BBO-10203，一种首创的口服破坏 RAS:PI3Kα 相互作用的药物，在 KRAS 突变模型中抑制肿瘤生长且未引发高血糖，将于 10 月 25 日 12:30–16:00 ET 在海报会场 C 由 Kerstin Sinkevicius 博士进行报告。摘要可在 AACR 网站获取。
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced poster presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held on October 22-26, 2025, in Boston, Massachusetts. The abstracts released today can be found on the AACR website here.
Details on the abstracts are as follows:
- Title: BBO-11818: an orally bioavailable, highly potent and selective non-covalent pan-KRAS(ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models
- Session: Poster Session A
- Session Date/Time: Thursday, October 23, from 12:30 p.m. – 4:00 p.m. ET
- Presenter: Carlos Stahlhut, PhD, Associate Director, BBOT
- Title: BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction inhibits tumor growth alone and in combination with KRAS inhibitors in KRAS mutant models without inducing hyperglycemia
- Session: Poster Session C
- Session Date/Time: Saturday, October 25, from 12:30 p.m. – 4:00 p.m. ET
- Presenter: Kerstin Sinkevicius, PhD, Vice President, Pharmacology, BBOT
About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.
BBOT Contacts:
Investor Contact:
Heather Armstrong, Head of Investor Relations
BBOT
Investors@BBOTx.com
Media Contact:
Jake Robison
Inizio Evoke Comms
Jake.robison@inizioevoke.com
FAQ
When will BBOT present BBO-11818 at the 2025 AACR-NCI-EORTC conference?
What is BBO-11818 and which BBOT presenter will discuss it (BBOT)?
When and where will BBOT present BBO-10203 at the AACR-NCI-EORTC 2025 conference?
What is the reported preclinical finding for BBOT's BBO-10203 (BBOT)?
How can investors view BBOT's abstracts from the AACR-NCI-EORTC conference?
What conference and dates cover BBOT's poster presentations (BBOT)?
